New drug duo shows promise against Tough-to-Treat kidney cancer
NCT ID NCT04704219
Summary
This study tested a combination of two drugs, pembrolizumab and lenvatinib, for people with an advanced form of kidney cancer that had spread and had not been treated before. The goal was to see how well the drugs worked together to shrink tumors and control the cancer. Researchers enrolled 160 participants to measure tumor response, how long the treatment worked, and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ankara University Hospital Cebeci ( Site 1105)
Ankara, 06100, Turkey (Türkiye)
-
Asan Medical Center-Department of Oncology ( Site 1300)
Seoul, 05505, South Korea
-
Ashford Cancer Centre Research ( Site 0404)
Kurralta Park, South Australia, 5037, Australia
-
Azienda Ospedaliera Santa Maria Terni-SC Oncologia ( Site 0900)
Terni, 05100, Italy
-
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma-Oncology Unit ( Site 0902)
Verona, Veneto, 37134, Italy
-
BC Cancer Vancouver-Clinical Trials Unit ( Site 1500)
Vancouver, British Columbia, V5Z 4E6, Canada
-
Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Okta-Klinikai Onkológiai és Sugárterápiás C
Miskolc, Borsod-Abauj Zemplen county, 3526, Hungary
-
CHU de Quebec - Université Laval - Hotel Dieu de Quebec ( Site 1502)
Québec, Quebec, G1R 3S1, Canada
-
CNPE "Regional Center of Oncology"-oncourology department ( Site 0502)
Kharkiv, Kharkivs’ka Oblast’, 61070, Ukraine
-
Calvary Mater Newcastle ( Site 0403)
Waratah, New South Wales, 2298, Australia
-
Cambridge University Hospital ( Site 1200)
Cambridge, England, CB2 0QQ, United Kingdom
-
Centre François Baclesse ( Site 1000)
Caen, Calvados, 14076, France
-
Centre de Cancérologie du Grand Montpellier ( Site 1005)
Montpellier, Languedoc-Roussillon, 34070, France
-
Cherkasy Regional Oncology Dispensary ( Site 0504)
Cherkassy, Cherkasy Oblast, 18009, Ukraine
-
Chernihiv Medical Center of Modern Oncology ( Site 0509)
Chernihiv, Chernihiv Oblast, 14029, Ukraine
-
Comprehensive Cancer Centers of Nevada ( Site 0010)
Las Vegas, Nevada, 89169, United States
-
Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 0300)
Debrecen, 4032, Hungary
-
Dnepropetrovsk Regional Clinical Hospital Mechnikov-Department of urology ( Site 0508)
Dnipro, Dnipropetrovsk Oblast, 49005, Ukraine
-
Ege University Medicine of Faculty ( Site 1102)
Bornova, İzmir, 35100, Turkey (Türkiye)
-
Fiona Stanley Hospital ( Site 0402)
Murdoch, Western Australia, 6150, Australia
-
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0903)
Milan, Lombardy, 20133, Italy
-
Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 0901)
Rome, Lazio, 00168, Italy
-
Fox Chase Cancer Center ( Site 0011)
Philadelphia, Pennsylvania, 19111, United States
-
Fundación Instituto Valenciano de Oncología-Oncologico ( Site 0202)
Valencia, Valenciana, Comunitat, 46009, Spain
-
Georgetown University Medical Center ( Site 0001)
Washington D.C., District of Columbia, 20007, United States
-
Gustave Roussy ( Site 1002)
Villejuif, Val-de-Marne, 94800, France
-
Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 1103)
Istanbul, 34722, Turkey (Türkiye)
-
Hacettepe Universitesi-oncology hospital ( Site 1101)
Ankara, 06230, Turkey (Türkiye)
-
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0201)
Barcelona, 08035, Spain
-
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 0200)
Madrid, Madrid, Comunidad de, 28034, Spain
-
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 1007)
Strasbourg, Alsace, 67200, France
-
Istanbul Universitesi Cerrahpasa ( Site 1104)
Istanbul- Fatih, Istanbul, 34098, Turkey (Türkiye)
-
Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 0303)
Szolnok, Jász-Nagykun-Szolnok, 5000, Hungary
-
Luxmed Onkologia sp. z o. o. ( Site 0802)
Warsaw, Masovian Voivodeship, 01-748, Poland
-
MEDICAL COLLEGE OF WISCONSIN ( Site 0006)
Milwaukee, Wisconsin, 53226, United States
-
Macquarie University-MQ Health Clinical Trials Unit ( Site 0405)
Macquarie Park, New South Wales, 2109, Australia
-
Memorial Sloan Kettering Cancer Center ( Site 0015)
New York, New York, 10065, United States
-
Monash Health ( Site 0400)
Clayton, Victoria, 3168, Australia
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
Warsaw, Masovian Voivodeship, 02-781, Poland
-
Nizhegorodsky Regional Oncology Dispensary, Branch #2-chemotherapy ( Site 0605)
Nizhny Novgorod, Nizhny Novgorod Oblast, 603081, Russia
-
Országos Onkológiai Intézet-Urogenital Tumors Department and Clinical Pharmacology ( Site 0304)
Budapest, Pest County, 1122, Hungary
-
Princess Margaret Cancer Centre ( Site 1504)
Toronto, Ontario, M5G 2M9, Canada
-
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si
Brisbane, Queensland, 4029, Australia
-
Russian Scientific Center of Radiology-Russian Scientific Center of Radiology ( Site 0602)
Moscow, Moscow, 117485, Russia
-
SHBI Leningrad Regional Clinical Oncology Dispensary-Clinical Trials Department ( Site 0607)
Saint Petersburg, 188663, Russia
-
Samsung Medical Center ( Site 1301)
Seoul, 06351, South Korea
-
Seattle Cancer Care Alliance ( Site 0014)
Seattle, Washington, 98109, United States
-
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1302)
Seoul, 03722, South Korea
-
St. Vincent Frontier Cancer Center ( Site 0004)
Billings, Montana, 59102, United States
-
Sunnybrook Health Sciences Centre ( Site 1501)
Toronto, Ontario, M4N 3M5, Canada
-
Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu M-chemotherapy department ( Site 0800)
Poznan, Greater Poland Voivodeship, 60-569, Poland
-
Tallaght University Hospital ( Site 1600)
Dublin, D24 NR0A, Ireland
-
The Christie ( Site 1205)
Manchester, M20 4BX, United Kingdom
-
Vanderbilt University Medical Center ( Site 0008)
Nashville, Tennessee, 37232, United States
-
Volga District Medical Center-Urology Department ( Site 0604)
Nizhny Novgorod, Nizhny Novgorod Oblast, 603074, Russia
-
centre hospitalier lyon sud ( Site 1003)
Pierre-Bénite, Rhone, 69310, France
Conditions
Explore the condition pages connected to this study.